To check Oneindia News on your Mobile
go to:   http://m.oneindia.in/news/
  •  

Infy to face visa fee hike with extreme offshoring

Infosys logo
Bangalore, Aug 31: At the setback when the whole world especially the Indian IT companies are worried about US H1-B, L1 visa fee hike decision, Infosys came up with an 'extreme offshoring' model to decrease dependence on those visas.

According the year ended result on 31 Mar, 2010, Infosys' onsite revenue were around Rs 10,461.32 crore (46.7 percent) and offshore revenues were Rs 12,121.5 crore, (53.3 percent).

However, the company said that it has capability to increase its offshore utilization capabilities to 95 percent, Business Standard reported.

According the company, the intention was to prepare the company to face an extreme situation should negative sentiment brewing in the US intensify further.

Pilot programmes have been conducted by the company with a couple of clients in the US.

The outcome of the programme has proven the model, which is expected to have a far-reaching impact on the delivery of IT services.

By sitting at remote offshore locations, the company successfully transitioned outsourced projects to India.

What is Extreme Offshoring:


  • Bringing more jobs back to India
  • Visa renewals to slow down
  • Less number of job created in US
  • Profit margins to go up
  • Hybrid delivery model may end
  • Nearshore to get some prominence

OneIndia News

B'lore: Infy techie turns suspect in wife's murder

Bangalore, Aug 11: A new twist has emerged in the murder of the Infosys techie's wife here, as the police is now questiong the husband and other relatives to see if any of them had any motive.According to a report in.....

Biotechnology major Biocon forays into nephrology space

Bangalore, Mar 09:  Biotechnology major Biocon on Thursday forayed into the nephrology space with the launch of a portfolio of five renal therapy products for the domestic and global markets, which it said was cheaper compared to MNC drug prices. The new immunosuppressants for renal therapy are at least 35-40 per cent cheaper than the MNC drug prices in the similar product category, the company's Marketing Head Rakesh Bamzai said.The Bangalore-headquartered company's Chairman and Managing Director, Kiran Mazumdar-Shaw said.....
User Comments
[ Post Comments ]
Be the first to comment on this article.
Oneindia  Oneindia Login